BTIG Research reissued their buy rating on shares of Impax Laboratories, Inc. (NASDAQ:IPXL) in a research note released on Saturday. The brokerage currently has a $27.00 price target on the specialty pharmaceutical company’s stock, up from their prior price target of $20.00.

Several other analysts also recently weighed in on the stock. Deutsche Bank AG reaffirmed a buy rating and issued a $23.00 target price on shares of Impax Laboratories in a report on Tuesday, September 19th. Citigroup Inc. lifted their target price on shares of Impax Laboratories to $23.00 and gave the company a buy rating in a report on Tuesday, September 19th. Piper Jaffray Companies reaffirmed a hold rating and issued a $17.00 target price on shares of Impax Laboratories in a report on Sunday, September 17th. Cantor Fitzgerald lifted their target price on shares of Impax Laboratories from $20.00 to $25.00 and gave the company an overweight rating in a report on Monday, September 11th. Finally, Royal Bank Of Canada set a $17.00 target price on shares of Impax Laboratories and gave the company a hold rating in a report on Thursday, August 10th. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating and five have assigned a buy rating to the company. Impax Laboratories has a consensus rating of Hold and an average price target of $19.03.

Impax Laboratories (NASDAQ IPXL) traded down 3.36% during midday trading on Friday, reaching $23.00. 1,568,934 shares of the company’s stock traded hands. Impax Laboratories has a 1-year low of $7.75 and a 1-year high of $27.29. The company’s market capitalization is $1.65 billion. The firm’s 50 day moving average price is $19.12 and its 200-day moving average price is $15.63.

Impax Laboratories (NASDAQ:IPXL) last issued its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.14 by $0.04. The company had revenue of $202.08 million for the quarter, compared to the consensus estimate of $195.62 million. Impax Laboratories had a negative net margin of 71.08% and a positive return on equity of 9.05%. Impax Laboratories’s revenue for the quarter was up 17.1% on a year-over-year basis. During the same period last year, the firm posted $0.21 EPS. Equities analysts expect that Impax Laboratories will post $0.70 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Impax Laboratories, Inc. (IPXL) Given Buy Rating at BTIG Research” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/09/24/impax-laboratories-inc-ipxl-given-buy-rating-at-btig-research.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Advisory Services Network LLC acquired a new stake in shares of Impax Laboratories in the second quarter valued at about $207,000. WINTON GROUP Ltd acquired a new position in Impax Laboratories during the second quarter worth about $1,066,000. Public Employees Retirement System of Ohio raised its position in Impax Laboratories by 12.7% during the second quarter. Public Employees Retirement System of Ohio now owns 6,911 shares of the specialty pharmaceutical company’s stock worth $111,000 after acquiring an additional 780 shares during the last quarter. Piedmont Investment Advisors LLC acquired a new position in Impax Laboratories during the second quarter worth about $257,000. Finally, Maverick Capital Ltd. raised its position in Impax Laboratories by 6,705.5% during the second quarter. Maverick Capital Ltd. now owns 7,159,336 shares of the specialty pharmaceutical company’s stock worth $115,265,000 after acquiring an additional 7,054,136 shares during the last quarter. Hedge funds and other institutional investors own 86.26% of the company’s stock.

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Analyst Recommendations for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.